Aileron Therapeutics, Inc. announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024. Dr. Windsor succeeds Manuel Aivado, M.D., Ph.D., who has stepped down as CEO and will continue to serve on the Company?s Board of Directors. The transition follows the Company?s acquisition of Lung Therapeutics, Inc. in October of last year.

Dr. Windsor has previously served as President and Chief Operating Officer of Aileron since October 2023. Prior to Aileron, he served as President, CEO and director of Lung. He has also served as Chief Science Officer Pharmaceuticals, Inc., for which Dr. Windsor had previously provided consulting services in the areas of science and technology.

Before his position at Lung, he served as President of Enavail, LLC, where he oversaw all aspects of the company?s pharmaceutical drug development. Before joining Enavail, he directed portfolio company management for Emergent Technologies, Inc., where he served as Managing Director or President for ten portfolio companies. Dr. Windsor holds a B.S. and a Ph.D. in Molecular Biology, both from The University of Texas at Austin.